Paul Pearson

Paul is President of Pearson Pharma Partners where he serves biotechnology and pharmaceutical companies and the National Institutes of Health in the areas of drug discovery, pharmacokinetics, drug metabolism, clinical pharmacology and drug interactions. Previously, he served as Global Head of Pharmacokinetics and Drug Metabolism at Amgen, the world’s largest biotechnology company. Prior to that, Paul served as Executive Director of Preclinical Drug Metabolism at Merck Research Laboratories. He has also held key positions at the Upjohn Company and has made major contributions to approvals of therapeutic agents to treat cancer and infectious diseases. Paul is the editor of the Handbook of Drug Metabolism (2019) and has published extensively in the field. He received his Pharmacy degree and Ph.D. in Pharmaceutical Sciences from Aston University, England, and completed post-doctoral training at the University of Washington. Paul is actively engaged in the discovery and development of new human therapeutics in the fields of oncology and neuroscience to make a dramatic difference to the lives of patients.